The difference between Ribociclib and Ribociclib

Ribociclib (Ribociclib) and Ribociclib are the same drug, but the names they are marketed in different regions may be different. Common names may be Ribociclib, Ribociclib Succinate Tablets, Ribociclib Succinate Tablets, Ribociclib, Ribociclib, KISQALI, KISQALI, and Kaililong.

After Ribociclib is approved by the U.S. Food and Drug Administration (FDA), it is suitable for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It can be used in combination with aromatase inhibitors or fulvestrant as initial endocrine therapy, or for women who have received endocrine therapy in the past. For premenopausal or perimenopausal women, endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist. Riboxiclib is a cancer growth retardant that slows tumor growth by inhibiting the activity of cyclin-dependent kinases 4 and 6 (CDK4/6), preventing cancer cell proliferation and division. Cell cycle-dependent kinases 4 and 6 (CDK4/6) are enzymes that have been shown to promote cell division and proliferation in normal and cancer cells.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.